Dual targeting of metastatic breast cancer improves survival rates
A new study from the USC Norris Comprehensive Cancer Center showed that targeting both hormone receptors (HRs) and human epidermal growth factor receptor 2 (HER2) in first-line treatment of metastatic breast cancer (MBC) patients significantly increased overall survival times.
Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.